Blaha, M., et al
In selecting a third agent added to metformin and DPP4 inhibitor, the ADA/EASD guidelines recommend selecting one of the agents among sulfonylurea, thiazolidinedione, SGLT-2 inhibitor or insulin, whereas other agents, including -glucosidase inhibitor, are generally not favored because of their modest efficacy and frequency of administration [2]
These products typically work by reducing the absorption of fat from food, but they come with potential side effects and varying levels of effectiveness
Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which occur in approximately 16-44% of patients depending on the product and dose according to clinical trials
But the fact that it is larger does not make it more important